60/734,640 OCT 1 B 2004

Under the Paperw

Sheet

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

RADIAN Substitute for form 1449B/PTO Complete if Known 10/734,640 INFORMATION DISCLOSURE **Application Number** STATEMENT BY APPLICANT Filing Date 12/15/2003 **Bruno DE LIGNIERES** First Named Inventor Date Submitted: October 18, 2004 **Group Art Unit** 1614 (use as many sheets as necessary) **Examiner Name** Not yet assigned of Attorney Docket Number 029488-0111

				U.S. PATENT DOCUMENTS	3	
Examiner Initials*	0.11-	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
W	A1	4,919,937		Pierre Mauvais-Jarvis	4/24/1990	
				L		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent D Number ⁴	ocument Kind Code (if known)	Name of Patentee o Applicant of Cited Docum		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
<u> </u>	French	A2 —	J. BARRAT et al., "Effet in vivo de l'administration locale de progestérene sur l'activité mitotique des galactophores humains", J. Gynecol. Obstet. Biol. Reprod. 19: 269-274-1990.	
	UL	А3	Bronaugh & Maibach, "Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology", Marcel Dekker Inc., New York, 1999.	
	a	A4	Philip CARTHEW et al., "Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat", Arch Toxicol (2001) 75: 375-380.	
	ll	A5	Gerard CHETRITE et al., "Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells", Anticancer Research 13: 931-934 (1993).	
	CH	A6	Eric C. DIETZE et al., "Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(-) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization", The Journal of Biological Chemistry Vol. 276, No. 7, Issue of February 16, 2001, pp. 5384-5394.	

Examiner Signature	hetal	Date Considered	2/23/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute fo	r form 1449B	/PTO	Complete if Known		
	INFORMATIO	ON DISCLO	SURE	Application Number	10/734,640	
	STATEMENT	ΓBY APPLI	CANT	Filing Date	12/15/2003	
	Data Submitta	d: October 1	18 2004	First Named Inventor	Bruno DE LIGNIERES	
Date Submitted: October 18, 2004				Group Art Unit	1614	
	(use as many s	heets <u>as ne</u>	cessary)	Examiner Name	Not yet assigned	
Sheet	2	of	4	Attorney Docket Number	029488-0111	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ [¢]
SL	A7	lan S. FENTIMAN, "Tamoxifen and Mastalgia an Emerging Indication", Drugs, Vol. 32, No. 6, December 1986, pp. 477-480.	
ll	A8	I.S. FENTIMAN et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial", BR. J. SURG. September 1988, Vol. 75, No. 9, pp. 845-846.	
12	A9	I.S. FENTIMAN et al., "Studies of tamoxifen in women with mastalgia*", The British Journal of Clinical Practice, Supplement 68, Vol. 43, No. 11, November 1989, pp. 34-36.	
ll	A10	N. GIAMBIAGI et al., "IMMUNOLOGICAL DIFFERENCES BETWEEN THE ESTRADIOL-, TAMXIFEN- AND 4-HYDROXY-TAMOXIFEN-ESTROGEN RECEPTOR COMPLEXES DETECTED BY TWO MONOCLONAL ANTIBODIES", J. Steroid Biochem. Vol. 30, No. 1-6, pp. 213-217, 1988.	
CR	A11	IBIS investigators, "First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial", The Lancet, Vol. 360, September 14, 2002, pp. 817-824.	
12	A12	V. Craig JORDAN et al., "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance", Breast Cancer Research and Treatment, 2, pp. 123-138.	
V2	A13	George G.J.M. KUIPER et al., "Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β ", Endocrinology, Vol. 138, No. 3, 1997, pp. 863-870.	
	A14	Frédérique KUTTENN et al., "MÉDECINE ET THÉRAPEUTIQUE", C.R. Acad. Sc. Paris, , Série III, No. 12, 1985, 300:457-461.	
CP	A15	Catherine MALET et al., "Tamoxifen and Hydroxytamoxifen Isomers versus Estradiol Effects on Normal Human Breast Cells in Culture", Cancer Research, Vol. 48, No. 24, December 15, 1988, pp. 7193-7199.	

Examiner Signature	Chaifate	Date Considered	2/23/67

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In. French

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE	Application Number	10/734,640	
STATEMENT BY APPLICANT	Filing Date	12/15/2003	
Date Submitted: October 18, 2004	First Named Inventor	Bruno DE LIGNIERES	
Date Submitted. October 10, 2004	Group Art Unit	1614	

(use as many sheets as necessary) **Examiner Name** Not yet assigned Sheet of Attorney Docket Number 029488-0111

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
12	A16	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Adminstration to Human Breast", Cancer Research, Vol. 46, March 1986, pp. 1521-1525.	
l	A17	Henri PUJOL et al., "Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue", Cancer Chemother. Pharmacol., 36:493-498 (1995).	
CL	A18	David W. ROBERTSON et al., "Synthesis of the E and Z Isomers of the Antiestrogen Tamoxifen and Its Metabolite, Hydroxytamoxifen, in Tritium-Labeled Form", J. Org. Chem., 1982, Vol. 47, No. 12, pp. 2387-2393.	
U-	A19	David W. ROBERTSON et al., "TAMOXIFEN ANTIESTROGENS, A COMPARISON OF THE ACTIVITY, PHARMACOKINETICS, AND METABOLIC ACTIVATION OF THE CIS AND TRANS ISOMERS OF TAMOXIFEN" Journal of Steroid Biochemistry, Vol. 16, pp. 1-13, (1982).	
ll	A20	Fabrice SAUVEZ et al., "Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats", Carcinogenesis Vol. 20, No. 5, pp. 843-850 1999.	
12	A21	John N. WOLFE MD, "RISK FOR BREAST CANCER DEVELOPMENT DETERMINED BY MAMMOGRAPHIC PARENCHYMAL PATTERN", Cancer, May 1976, Vol. 37, No. 5, pp. 2486-2492.	
VL	A22	Deborah N. ADER PhD, et al., "Prevalence and impact of cyclic mastalgia in a United States clinic-based sample", Am. J. Obstet. Gynecol., Vol. 177, No. 1, pp. 126-132, July 1997.	-
V_	A23	M.R. CALLANTINE PhD. et al., "Micronized 17β-Estradiol for Oral Estrogen Therapy in Menopausal Women", Obstetrics & Gynecology Vol. 46, No. 1, July 1975, pp. 37-41.	
W	A24	A. GORINS et al., "A FRENCH DOUBLE-BLIND CROSSOVER STUDY (DANAZOL VERSUS PLACEBO) IN THE TREATMENT OF SEVERE FIBROCYSTIC BREAST DISEASE", Eur. J. Gynaec. Oncol. Vol. 2, 1984, pp. 85-89.	
le	A25	S.J. Graham PhD, "Changes in Fibroglandular Volume and Water Content of Breast Tissue During the Menstrual Cycle Observed by MR Imaging at 1.5 T", JMRI, Vol. 5, No. 6, November/December 1995, pp. 695-701.	

Examiner Signature	theoffled	Date Considered	2/23/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ¹See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁰Applicant is to place a check mark here if English language Translation Is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	or form 1449B	/PTO		Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	10/734,640		
l	STATEMEN	T BY APPLI	ICANT	Filing Date	12/15/2003	· · · · · · · · · · · · · · · · · · ·	
	Date Submitte	d: October 1	19 2004	First Named Inventor	Bruno DE LIGNIERES		
	Date Submitte	d. October	10, 2004	Group Art Unit	1614		
	(use as many :	sheets as ne	ecessary)	Examiner Name	Not yet assigned		
Sheet	4	of	4	Attorney Docket Number	029488-0111		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
U	A26	R.E. MANSEL et al., "A Double Blind Trial of the Prolactin Inhibitor Bromocriptine in Painful Benign Breast Disease", Br. J. Surg. Vol. 65, (1978), pp. 724-727.	
H	A27	Catherine S. MURPHY et al., "Structure-Function Relationships of Hydroxylated Metablolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Molecular Pharmacology, 38, pp. 737-743, (1990).	
LL	A28	Lawrence H. BLOCK, PhD, "Epidermal and Transdermal Drug Delivery", Medicated Topicals, Chapter 44, Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro, Lippincott Williams and Wilkins, 2000, pp. 836-858.	
4	A29	M. SAMBROOK et al., "Ultrasonic Doppler Study of the Hormonal Response of Blood Flow in the Normal Human Breast", Ultrasound In Med. & Biol. Vol. 13, No. 3, pp. 121-129 (1987).	
	,		

Examiner Signature	the Takel	Date Considered	423/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

10/734,640

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.		_				- SIPE
	Substitute fo	r form 1449B	/PTO		Complete if Known	18
	INFORMATION	ON DISCLO	SURE	Application Number	10/734,640	8
	STATEMEN'	T BY APPLI	CANT	Filing Date	12/15/2003	. MAR 0 3 2005 y
	Date Submitt	ed: March 3	2005	First Named Inventor	Bruno DE LIGNIERES	
	Date Outmitt	cu. March 5	, 2003	Group Art Unit	1614	6 .
	(use as many s	heets as ne	cessary)	Examiner Name	Unassigned	PADEMARK.
Sheet	1	of	1	Attorney Docket Number	029488-0111	

	U.S. PATENT DOCUMENTS										
Examiner Initials*		U.S. Patent (Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines,					
	Cite No. ¹	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear					

Examiner Initials*	Cite No.1	Offic	Foreign Patent Document	The second of th	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
VIC		B1	DE 38 36 862 A1	Gunther Clemens et al.	5/3/1990		
							\vdash

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*						
		•				

Examiner Signature	Chefclent	Date Considered	423/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

Substitute for form 1449B/PTO					Complete if Known		0/2	
	INFORMATIO	N DISCLO	SURE	Application Number	10/734,640	7		፟
	STATEMENT	BY APPLI	CANT	Filing Date	12/15/2003	R JUN		**
	Date Submitte	ad: Juna 2	2005	First Named Inventor	Bruno DE LIGNIERES		2200	핓
•	Date Submitte	su. June 2,	2005	Group Art Unit	1614	2	-oa	₹.
	(use as many sh	eets as ne	cessary)	Examiner Name	Unassigned	V3 .	<	7
Sheet	1	of	1	Attorney Docket Number	029488-0111	र्ण्य	ARK OF	_

				U.S. PATENT DOCUMENTS	•		
Examiner Gite		U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials* No.1	No.1	Number	Kind Code ² (if known)	Document	Gited Document MM-DD-YYYY	Figures Appear	
MC	C1	4 919 937	T	Mauvais-Jarvis et al.	4/24/1990		
WL_	(2	2003/0153543 A1		Masato TANABE et al.	8/14/2003		
in	C3	5 189 212		University of Georgia Research Foundation	2/23/1993		

	·			FOREIGN PATENT DOCUMENTS			
Examiner Cite Initials No.1	Cite	Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
	No.¹	Office ³ Number ⁴ Kind Code ⁵ (if knomi)		Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	Te.
<u>u</u>	C4	EP 0 792 640 A2		PFIZER INC.	9/3/1997		
- (N	C5	EP 1 106 179 A2		PFIZER INC.	6/13/2001		
19	C6	WO 02/36129 A2		Alfred SCHMIDT et al.	5/10/2002		T
412	(7	WO 02/03969 A2		HEXAL AG	1/17/2002		1
11	C8	EP 1 177 787 A2		Pfizer Products Inc.	2/6/2002		T
							7

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Тe
Ve	C9	International Search Report of PCT/EP03/15028	
	C10	P. MALVAIS-JARVIS, "Le traitement hormonal des mastopathies benignes", Bull Cancer (1991) 78, 365-371.	
W	C11	I.S. FENTIMAN et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial", Br. J. Surg. 1988, Vol. 75, September, 845-846.	
M	C12	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen concentration and Metabolism after Local percutaneous Administration to Human Breast", Cancer Research 46, 1521-1525, March 1986.	
VR	C13	Henri PUIOL et al., "Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue", Cancer Chemother Pharmacol., 1995, 36: 493-498.	

Examiner Signature	(latelal	Date Considered	423/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Cen

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

di Dadinellan Art of 1005 m

under the Paperwork	neduction Act of 1995, no p	ersons a	re required to respo	ing to a collection of information unless it contain	is a valid OMB control number.	
	Substitute for form 14	498/PT	0		Complete if Known	OIPE
	INFORMATION DIS	CLOSUR	E	Application Number	10/734,640	7
	STATEMENT BY AF	PLICAN	T	Filing Date	12/15/2003	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	Date Submitted: Noven	her 8	2005	First Named Inventor	Bruno DE LIGNIERES	NOV 0 8 2005 12
	vale Jubilitied. Moveli	וטכו ס, ו	2003	Group Art Unit	1617	2003
	(use as many sheets a	s песеs	sary)	Examiner Name	Jennifer M. Kim	(I)
Sheet	1	of	1	Attorney Docket Number	029488-0111	MADEMARKO

		•		U.S. PATENT DOCUMENTS		
Examiner	Cite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant
Initials*	No.1	Number	Kind Code ² (if known)	Document	Cited Document MM-DD-YYYY	Cited Document Passages or Relevant MM-DD-YYYY Figures Appear
1/1	D1	2002/0115676 A1		David B. MACLEAN	8/22/2002	
1	DZ	2003/0065017 A1		PFIZER INC.	4/3/2003	
17	D3	2003/0087885 A1		Valerie MASINI-ETEVE et al.	5/8/2003	
1/	D4	6,503,894 B1		Unimed Pharmaceuticals Inc. et al.	1/7/2003	
$\overline{}$	<u> </u>					
	1					

				PONEIGH FATERT DOCUMENTS	Data of Daktiontine of	D C.b	т
Gte		Foreign Patent Do	cument	Name of Patentee or		Relevant	
No.1	Office ¹	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	le
D5		WO 2004/110420	I A1	LABORATORIES BESINS INTERNATIONAL et al.	12/23/2004		
					•		╁
	No.1	No.1 Office	No. ¹ Office ³ Number ⁴	No.1 Office3 Number4 Kind Code5 (if known)	No.1 Office3 Number4 Kind Code5 (if known) Applicant of Cited Documents D5 WO 2004/110420 A1 LABORATORIES BESINS	Cite No.1 Office3 Number4 Kind Code5 (# known) Name of Patentee or Applicant of Cited Documents MM-DD-YYYY D5 W0 2004/110420 A1 LABORATORIES BESINS 12/23/2004	Gite No.1 Office3 Number4 Kind Code5 (# known) Name of Patentee or Applicant of Gited Documents MM-DD-YYYY Passages or Relevant Figures Appear

**		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials®	Cite No.1	ntem (book, magazine, journal, senal, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
N	D6	Lawrence N. PARKER et al., "Treatment of Gynecomastia with Tamoxifen: A Double Blind Crossover Study", Metabolism, Vol. 35, No. 8, 1986: pp. 705-708.							
			ļ -						
ا معن									

	Λ		
Examiner Signature	Chet Cle !	Date Considered	2/23/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with vext communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Tenter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language. English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB.control

number.						SIPE
	Substitute fo	r form 1449B/I	PTO		Complete if Known	· 48
	INFORMATIO	ON DISCLOS	SURE	Application Number	10/734,640	3
	STATEMENT	T BY APPLIC	CANT	Filing Date	12/15/2003	NOV 2 1 7005
	Date Submitted	· November '	21 2005	First Named Inventor	Bruno DE LIGNIERES	138
	Date Spontifice	. Hoveiliber a	21, 2003	Group Art Unit	1617	(3)
	(use as many s	heets as nec	essary)	Examiner Name	Jennifer M. Kim	RADIDAR
Sheet	1	of	1	Attorney Docket Number	029488-0111	

	U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
						·			

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	For Office ³	eign Patent C Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, . Where Relevant Passages or Relevant Figures Appear	T*
								T
								\top
								\top
			· · · · · · · · · · · · · · · · · · ·		<u> </u>	,		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
1 th	E1	BRISSON, J., et al., "Tamoxifen and Mammographic Breast Densities, Cancer Epidemiology, Biomarkers & Prevention, Vol. 9, pp. 911-915 (2000).	
U	E2	"High Breast Density a Risk Factor", pp. 1-4, http://www.breastcancer.org/research_genetics_091902_pf.html (8/11/05)	

Examiner Signature	1 let falwed	Date Considered	2/23/17	21. 1
AEW AARINED.	half a little of the control of the dead of the thought of the conference of the APER COO	Denve line through	citation if not in conformance	and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and n considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO).

Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/S8/08 (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/734,640 8/STATEMENT BY APPLICANT Filing Date 12/15/2003 Bruno DE LIGNIERES First Named Inventor E Submitted: February 13, 2006 1617 Group Art Unit use as many sheets as necessary) Examiner Name Jennifer M. Kim 029488-0111 Attorney Docket Number

	U.S. PATENT DOCUMENTS								
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Examiner Initials*	No.1	Number	Kind Code ² (# known)	Document	Cited Document MM-DD-YYYY	Figures Appear			
	+								
	+								

	U.S. PATENT APPLICATION DOCUMENTS										
Examiner	Cite	U.S. Patent Applicat	tion Document	Name of Patentee or Applicant of Cited	Filing Date of	Pages, Columns, Lines, Where Relevant Passages or Relevant					
Initials*	No.1	Serial Number	Kind Code ² (if known)	Document	Cited Document MM-DD-YYYY	Figures Appear					

					FOREIGN PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
Examiner Initials*	Cite No.'	Office	Foreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Retevant Passages or Relevant Figures Appear	le
	<u> </u>	-WO-	-2004/054557 A 2		LABORATOIRES BESINS INTERNATIONAL	7/1/2004		
-حز	F2-	_wo_	- 2004/ 05 4 5 58 A2		LABORATOIRES BESINS INTERNATIONAL	7/1/2004		
			1133					

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.!	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	16				
t.		·					

Examiner Signature Date Considered 2/23/2007	 			
	(he felul		an indus	1200

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/58/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

029488-0111

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete if Known Application Number INFORMATION DISCLOSURE, 10/734,640 STATEMENT BY APPLICANT **Filing Date** 12/15/2003 AUG 2 8 2006 Date Submitted: August 28, 2003 First Named Inventor Bruno DE LIGNIERES roup Art Unit 1617 PADEMAN (use as many sheets as necessar) Jennifer M. Kim **Examiner Name**

Attorney Docket Number

U.S. PATENT DOCUMENTS							
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number	Kind Code ² (#	Document	Cited Document MM-DD-YYYY	Figures Appear	
	G1	2004/0138314	A1	BUA	7/15/2004		
<u>. v</u>							
							
					1.		
			.1	•			

Examiner Initials*	Cite No.1	Foreign Patent Document Kind Code ⁵			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		Office	e ³ Number ⁴	(if known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	1e
1 1/	62	ЕP	1 579 857	A1	LABORATOIRES BESINS INTERNATIONAL	9/28/2005		
IN	G3	EP	1 579 856	A1	LABORATOIRES BESINS INTERNATIONAL	9/28/2005		
								L

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
-								
;								

Examiner Date Considered Z 23/200				
The decidence of the second se	Examiner Signature	Thetalel	Date Considered	1 (

*EXAMINER: Initial il reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet